RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. This is reflected with the value of the global antisense and RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. With Covid-19 rapidly accelerating the RNA landscape through massive regulatory successes, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, there has been considerable progress in the development of RNA medicines and a major expansion of the RNA-therapeutics field.

In 2023 we will see the return of SAE's RNA Therapeutics conference to a live in-person event, showcasing an update on mRNA therapeutic applications, coupled with an industry outlook of the field. We will also explore the latest trends in novel RNA therapies, including developments in AI modelling and small molecule modulation of RNA. Further topics to be examined comprise of novel RNA modalities encompassing self-amplifying RNA, saRNA, circular RNA, lnc RNA and many more.

Don't miss this unmissable opportunity to network with the pharma and biotech community of global experts in the UK and Europe; the two-day agenda offers you peer-to-peer networking with Directors of novel RNA therapies, CEOs, Senior and expert scientists, Chief Medical Officers, Senior Vice Presidents and many more.

Benefits of attending:
- Explore how mRNA leads the way in the genetic medicine space as the next generation of novel drug modalities
- Investigate the latest trends in AI drug discovery as a tool for designing novel RNA based therapeutics
- Enhance your knowledge of the latest innovations in RNA application and RNA delivery techniques with case studies from BioNTech, Neuway Pharma and Ethris GmbH
- Engage in the growing advances and development of novel RNA molecules in the treatment of chronic respiratory, neurodegenerative, and infectious diseases

Who should attend:
- Directors of novel RNA therapies
- CEOs
- Senior and expert scientists
- Chief Medical Officers
- Chief Technical Officers
- Senior Vice Presidents
- Global Heads of mRNA R and D
- Global Medical Directors
- Heads of Translational Medicine
- Director, Clinical Pharmacology
- Global Head of RNA and Targeted Therapeutics
- Clinical Science Director
- Head of Biology
- Director, Genetic Medicine
- Associate Director

Read on go.evvnt.com

Continue reading at smgconferences.com

Health and Wellness

Facebook Share

Twitter Share

Linkedin Share

Email Share